Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events by Tomasz K Wojdacz et al.
SHORT REPORT Open Access
Methylation of cancer related genes in tumor and
peripheral blood DNA from the same breast
cancer patient as two independent events
Tomasz K Wojdacz 1,2,3*, Britta B Thestrup3, Jens Overgaard2,3† and Lise Lotte Hansen3†
Abstract
Background: Recently it has been suggested that acquisition of methylation of the BRCA1 promoter detectable in
peripheral blood (PB) DNA, could give raise to development of breast cancer. In this study, we aimed to investigate
a relationship between methylation of three breast cancer related genes in PB DNA, and tumor specific (somatic)
methylation of these genes in the same individual.
Findings: We have examined methylation status of the BRCA1, APC and RASSF1A promoter regions in a panel of 75
breast tumor and PB DNA samples from the same individual. In our study group, 4.0% of the patients displayed
methylation of BRCA1 and APC in both tumor and the corresponding PB DNA. At the same time despite of marked
methylation in tumor DNA, no methylation of BRCA1 and APC was seen in PB DNA of 4.3% and 2.7% of the
patients respectively. The RASSF1A promoter did not show methylation in PB DNA.
Conclusions: Our results show that for at least a subset of cancer patients methylation of certain cancer related
genes in PB DNA does not seem to be directly linked to somatic methylation of the same genes in tumor DNA,
and therefore may only be specific to PB DNA.
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The mechanism of methylation dependent gene deactiva-
tion and its significance to cancer pathogenesis is well
described, with hypermethylation of tumor suppressor
genes, affecting transcriptional activity of the genes, con-
sidered to be one of the most important drivers of carci-
nogenesis. Recently, much attention is paid to the
phenomenon of hypermethylation of disease related
genes in peripheral blood (PB) DNA and its involvement
in the pathology of cancer and other diseases [1-6]. The
origins of this phenomenon are unknown. However, it
can be hypothesized that aberrant methylation of genes
in PB DNA may be a consequence of germ line trans-
mitted methylation changes or somatic aberrations that
occurred during early development or through life time
under specific environmental conditions. Transmission
of methylation changes through germ line is still a pro-
blematic notion. There are only limited evidence showing
that methylation of certain genes e.g. MLH1 in some
cases can be passed through germ line in non-Mendelian
fashion [7-11]. Recently, two studies have shown that
paternal diet can have an influence on the methylation
pattern of the offspring [12,13]. This further supports the
significance of germ line transmission of methylation
changes, however, these findings have to be more exten-
sively researched in the future. As for environmental
pressure on the individuals methylome, the influence of
different chemicals on the somatic methylation pattern of
the exposed subjects has been demonstrated in animal
models, and proven to be especially damaging when the
exposure occurred in the early stages of development (as
reviewed in [14]). In humans there is mounting epide-
miological evidence that environmental exposure can
predispose to adult onset diseases. However it is still not
clear, how the interactions between individual organisms
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and the environment occur, and to what extent they
involve methylation changes.
Disregarding the origin, the intra individual methyla-
tion differences in human PB DNA are being increas-
ingly reported in the literature [4-6]. Furthermore, these
changes have been suggested to be a part of a disease
predisposition mechanism, which could be based on the
theory of constitutional methylation [2].
Constitutional gene methylation was initially defined as
abnormal gene methylation observed in all tissues of the
body [15]. Constitutional methylation is most likely affect-
ing genes in a mono allelic fashion and if acquired during
development, it can be distributed to all tissues of the
organism in a mosaic pattern (and therefore seen at very
low levels in affected tissues) [2,4]. Drawing analogy from
somatic methylation in cancer, constitutional mono allelic
methylation changes are likely to render the affected indi-
vidual prone to development of neoplastic (and other) dis-
eases. This is due to the fact that only one additional hit
would be required (according to Knudson’s hypothesis of
tumor suppressor deactivation [16]) to abolish expression
of the constitutionally mono allelic methylated gene and
initiate or contribute to carcinogenesis. Moreover, allelic
insufficiency could also be a disease-initiating factor.
In the first report, suggesting a link between methylation
of the BRCA1 promoter in PB DNA and development of
breast cancer with methylated BRCA1, the authors exam-
ined methylation status of the BRCA1 promoter in tumors
and PB DNA from three breast cancer patients [3]. They
showed that the BRCA1 promoter was methylated in both
PB DNA samples and matched tumor DNA in all exam-
ined individuals [3]. The observed methylation was never
seen at a level suggesting monoallelic specificity (50%
methylation) but only at low levels (5-14%) reflecting high
degree of mosaicism in the screened cell populations.
Despite the promising results of this study showing a puta-
tive elegant mechanism of direct contribution of constitu-
tional methylation to carcinogenesis, two follow up studies
did not result in similar conclusions. In those studies the
authors have examined methylation status of the BRCA1
promoter in PB and paired tumor DNA, however only a
subset of the tumors, developed by patients with PB
BRCA1 methylation, harbored tumor specific methylation
of BRCA1 [2,17]. The study by Wong et al. [2] involved 12
breast cancer patients with paired tumor and PB DNA
samples. The authors in this study reported generally low
levels of methylation detected in PB (for most of the sam-
ples less than 5%) and furthermore, three patients with
BRCA1 methylation in PB DNA did not display BRCA1
methylation in the paired tumor sample. A subsequent
study by Iwamoto et al. [17] showed a more significant
lack of direct correlation between methylation of BRCA1
in PB DNA and matched tumor samples.
Based upon the above results we aimed to investigate
the presence or absence of a correlation between DNA
methylation of cancer related genes in PB and paired
tumor DNA from breast cancer patients.
We hypothesized that if the observed methylation of
genes in PB DNA reflects constitutional methylation, the
same methylation pattern has to be present in tumor
DNA (as it originates from healthy tissue harboring con-
stitutional methylation of the specific gene). Conse-
quently if the methylation of those genes cannot be
found in tumor DNA, the methylation observed in PB
DNA is only specific to PB DNA (not constitutional) and
does not directly contribute (in this case) to breast carci-
nogenesis of the affected individual.
In our study methylation of the BRCA1, APC and
RASSF1A promoter regions was analyzed in 75 paired
breast tumor and PB DNA samples using the MS-HRM
(Methylation Sensitive High Resolution Melting) proto-
col. All MS-HRM assays were designed according to the
guidelines published in [18,19]. The primer sequences
used have been published in [20]. The regions targeted
by the assays, spanning promoters of the screened genes
are shown in Table 1. The experiments were performed
as previously described [21]. Briefly, tumor DNA was
extracted as described in [22], and a modified salting-out
protocol was used for purification of DNA from periph-
eral blood [23]. 100 ng of genomic DNA was bisulfite
modified using EpiTect Bisulfite Kit (Qiagen). The Ligh-
Cycler® 480 platform (Roche) was used for both PCR
amplifications and the subsequent HRM analyses. The
PCR mixes consisted of 1× LightCycler® 480 HRM Mas-
ter mix Roche, 3 mM Mg+2, 0.5 μM of each primer and 4
ng (theoretically) of bisulfite modified DNA template. All
reactions were run in triplicates. The methylation status
of each sample was scored by comparison of the HRM
profile of the sample to the HRM profiles obtained from
dilutions of the methylated bisulfite modified template in
an unmethylated background (Millipore). The data in
this study were analyzed as previously described [21],
where MS-HRM and Sanger sequencing were used to
confirm that any aberrations of the HRM profile from
the profile of the PCR product amplified from 0% methy-
lation template are positive for methylation. Due to the
fact that all published studies report the constitutional
methylation to occur at very low levels (mosaic fashion)
instead of the expected 50% methylation level that could
be anticipated for mono allelic methylation, our data ana-
lysis was similar to previously published results based on
qualitative methylation assessment. Nevertheless, MS-
HRM data allow for quantitative methylation measure-
ment and the Figures 1, 2 and 3 depict the representative
MS-HRM results. It can be argued that for the patients
displaying the same methylation pattern in tumor and PB
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Table 1 Frequencies of methylation of analyzed genes in PB and breast tumors.
GENE Chromosomal region targeted by assay
*
Number of paired samples used/
excluded**








BRCA1 chr17:41, 277, 382-41, 277, 409 75/6 3 (4.3%) 23% 3 (4.3%)
APC chr5:112, 073, 470-112, 073, 516 75/3 3 (4.1%) 83% 2 (2.7%)
RASSF1A chr3:50, 377, 755-50, 378, 089 75/2 0% 97% 0
* UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly
** Samples excluded due to failure of PCR amplification
















Figure 1 Representative results for MS-HRM based screening for APC methylation. Panel 1A, show the sensitivity of the assays with MS-
HRM profile characteristic for 100% - blue, 10% - green, 1%- pink and 0% - red, mixes of methylated template in unmethylated background.
Panel 1B, examples of PB sample positive (orange) and negative (brown) for methylation. Panel 1C, examples of the tumor sample positive
(orange) and negative (brown) for methylation.
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Figure 2 Representative results for MS-HRM based screening for BRCA1 methylation. Panel 1A, show the sensitivity of the assays with MS-
HRM profile characteristic for 100% - blue, 10% - green, 1%- pink and 0% - red, mixes of methylated template in unmethylated background.
Panel 1B, examples of PB sample positive (orange) and negative (brown) for methylation. Panel 1C, examples of the tumor sample positive
(orange) and negative (brown) for methylation.
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Figure 3 Representative results for MS-HRM based screening for RASSF1A methylation. Panel 1A, show the sensitivity of the assays with
MS-HRM profile characteristic for 100% - blue, 10% - green, 1%- pink and 0% - red mixes of methylated template in unmethylated background.
Panel 1B, example of PB sample positive (orange) for methylation. Panel 1C, examples of the tumor sample positive (orange) and negative
(brown) for methylation.
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DNA, the detectable in PB DNA methylation, is not PB
specific, but derived from circulating tumor cells and/or
free circulating tumor DNA. However, it was previously
shown that detection of tumor circulating cells is only
possible when using enrichment technologies [24], and
moreover our peripheral blood sample processing proto-
col dilutes free circulating tumor DNA and tumor cells
under detection limit of MS-HRM (as described in [2]).
All three genes analyzed in our study showed methyla-
tion in the tumor samples suggesting as previously
reported, their involvement in breast cancer pathogenesis
Table 1. We observed high frequencies of methylation
for all three genes, however the methylation frequencies
for APC and RASSF1A were higher than reported in the
literature http://www.pubmeth.org. This may be attribu-
ted either to an exceptionally high methylation preva-
lence in our samples or more likely to a high sensitivity
of the MS-HRM technology [25].
Two of the examined genes, BRCA1 and APC, showed
methylation in both tumor and paired PB DNA at fre-
quencies of 4.4% and 4.1%, respectively (see Table 1 for
details) with one of the paired samples showing methyla-
tion of both APC and BRCA1 in tumor and PB DNA.
However, at the same time three of the samples in our
panel did not show methylation of BRCA1 in tumor
DNA despite marked methylation in PB DNA. The same
was seen for APC in two of the samples. RASSF1A did
not show methylation in any of the PB samples.
Our study shows that a direct link between methylation
of cancer related genes in PB DNA and development of
cancer is questionable. If a direct link existed and as pre-
viously suggested detectable in PB DNA hypermethyla-
tion was constitutional [2], all patients with PB DNA
methylation should display the same specific methylation
pattern in the paired tumor. This is due to the fact that
tumor DNA originates from healthy tissue, which (simi-
lar to blood tissue) should harbor constitutional methyla-
tion that in turn would predispose the affected individual
to cancer development. The fact that we have not seen
the same methylation pattern for a subset of our paired
samples suggests independence of the methylation events
in PB DNA and during tumor development. However, at
the same time basing on current results, we cannot rule
out the presence of a direct link between those two
events for the subset of patients displaying methylation
in both PB and tumor DNA.
In conclusion, the fact that methylation of the BRCA1
gene in PB DNA correlates with increased risk of breast
cancer, allows to anticipate that aberrant methylation of
genes in PB and disease predisposition are linked. Espe-
cially considering the study by Iwamoto et al. and the
study by Wong at al. both indicating a strong correlation
between methylation of BRCA1 in PB and breast cancer
incidence. However, our present and previously
published results do not confirm that the mechanism of
that interaction is based solely on constitutional methyla-
tion and suggests independence of those two events for
at least a subset of cancer patients.
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